Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters

Objective To monitor changes with gestation in levels of alpha‐fetoprotein (AFP), free beta human chorionic gonadotrophin (FβhCG) and pregnancy associated plasma protein‐A (PAPP‐A) in Down's syndrome pregnancies and to compare risks estimated in the first trimester with those obtained by routine screening in the second trimester for the same pregnancies.

[1]  A. Odibo.  Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy , 1996, British journal of obstetrics and gynaecology.

[2]  A. Lyon,et al.  Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. , 1996, The New England journal of medicine.

[3]  N. Wald,et al.  Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy , 1996, British journal of obstetrics and gynaecology.

[4]  D. Krantz,et al.  First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. , 1996, American journal of obstetrics and gynecology.

[5]  S. Cohn,et al.  Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[6]  J. Crossley,et al.  Analysis of maternal serum alpha‐fetoprotein and free beta human chorionic gonadotrophin in the first trimester: Implications for down's syndrome screening , 1995, Prenatal diagnosis.

[7]  K. Nicolaides,et al.  First trimester fetal nuchal translucency , 1995, Current opinion in obstetrics & gynecology.

[8]  M. Brizot,et al.  Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy , 1995, British journal of obstetrics and gynaecology.

[9]  K. Spencer,et al.  First Trimester Biochemical Screening for Trisomy 21: The Role of Free Beta hCG, Alpha Fetoprotein and Pregnancy Associated Plasma Protein A , 1994, Annals of clinical biochemistry.

[10]  J. Connor,et al.  Impact of a Regional Screening Programme Using Maternal Serum a Fetoprotein (AFP) and Human Chorionic Gonadotrophin (hCG) on the Birth Incidence of Down's Syndrome in the West of Scotland , 1994, Journal of medical screening.

[11]  S. Goodburn,et al.  Second‐trimester maternal serum screening using alpha‐fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme , 1994, Prenatal diagnosis.

[12]  J. Grudzinskas,et al.  Maternal serum human chorionic gonadotrophin and pregnancy‐associated plasma protein a, markers for fetal down syndrome at 8–14 weeks , 1994, Prenatal diagnosis.

[13]  K. Spencer,et al.  Maternal serum free beta hCG screening: Results of studies including 480 cases of down syndrome , 1994, Prenatal diagnosis.

[14]  N. Wald,et al.  Serum alpha‐fetoprotein and neural tube defects in the first trimester of pregnancy , 1993 .

[15]  K. Spencer,et al.  Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. , 1993, BMJ.

[16]  K. Spencer,et al.  First‐trimester biochemical screening for fetal chromosome abnormalities and neural tube defects , 1993, Prenatal diagnosis.

[17]  K. Spencer,et al.  First‐trimester free beta (hCG) screening for Down syndrome , 1993, Prenatal diagnosis.

[18]  W. Schmid,et al.  Ultrasound screening for chromosomal anomalies in the first trimester of pregnancy , 1993, Prenatal diagnosis.

[19]  T. Chard,et al.  Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype , 1993, British journal of obstetrics and gynaecology.

[20]  J. Canick,et al.  Prenatal screening for Down's syndrome with use of maternal serum markers. , 1992, The New England journal of medicine.

[21]  J. Grudzinskas,et al.  Pregnancy associated plasma protein A in Down's syndrome. , 1992, BMJ.

[22]  N. Wald,et al.  Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. , 1992, BMJ.

[23]  J. Grudzinskas,et al.  First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. , 1992, BMJ.

[24]  K. Spencer,et al.  Free β-hCG as first-trimester marker for fetal trisomy , 1992, The Lancet.

[25]  J. Yates,et al.  Estimating the risk of a fetal autosomal trisomy at mid‐trimester using maternal serum alpha fetoprotein and age: A retrospective study of 142 pregnancies , 1991, Prenatal diagnosis.

[26]  B. Crandall,et al.  First‐trimester maternal serum unconjugated oestriol and alpha‐fetoprotein in fetal Down's syndrome , 1991, Prenatal diagnosis.

[27]  J. Connor,et al.  Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha‐fetoprotein, and age , 1991, Prenatal diagnosis.

[28]  D. Brock,et al.  First‐trimester maternal serum biochemical indicators in Down syndrome , 1990, Prenatal diagnosis.

[29]  E. Hook,et al.  Maternal age-specific rates of 47,+21 and other cytogenetic abnormalities diagnosed in the first trimester of pregnancy in chorionic villus biopsy specimens: comparison with rates expected from observations at amniocentesis. , 1988, American journal of human genetics.

[30]  N J Wald,et al.  MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY Report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects , 1977, The Lancet.

[31]  J. Simpson.  ULTRASOUND MARKERS FOR FETAL CHROMOSOMAL DEFECTS , 1996 .

[32]  M. Whittle,et al.  Prenatal diagnosis in obstetric practice , 1989 .

[33]  D. Sillence,et al.  Prenatal screening. , 1986, Australian family physician.

[34]  J. Brooks-Gunn.  MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY: , 1978 .

[35]  M. Kanai,et al.  [Biochemical screening]. , 1976, Nihon rinsho. Japanese journal of clinical medicine.